<DOC>
	<DOCNO>NCT02200653</DOCNO>
	<brief_summary>The primary aim trial compare influence MICARDIS® ( telmisartan ) COZAAR® / LORZAAR® ( losartan ) lower ambulatory diastolic blood pressure ( DBP ) last 6 hour 24-hour dose interval measure ABPM . Secondary objective include evaluation : 1 ) change baseline mean systolic blood pressure ( SBP ) last 6 hour 24-hour dose interval measure ABPM , 2 ) change baseline SBP DBP period 24-hour ABPM profile , 3 ) change baseline mean seat trough SBP DBP measure manual cuff sphygmomanometer , 4 ) responder rate base ABPM trough cuff blood pressure</brief_summary>
	<brief_title>A Trial Comparing MICARDIS® ( Telmisartan ) COZAAR® / LORZAAR® ( Losartan ) Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring ( ABPM )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Mildtomoderate hypertension define mean seat diastolic blood pressure ≥ 95 mmHg ≤ 109 mmHg , measure manual cuff sphygmomanometer , Visit 3 ( baseline cuff BP ) A 24mean DBP ≥ 85 mmHg Visit 4 measure ABPM Age 18 year old Ability stop current antihypertensive therapy without risk patient ( investigator 's discretion ) Patient 's write informed consent accordance good clinical practice ( GCP ) local legislation Premenopausal woman ( last menstruation ≤ 1 year prior start runin period ) : surgically sterile ; and/or nursing childbearing potential NOT practise acceptable mean birth control , NOT plan continue use method throughout study . Acceptable method birth control include oral , implantable injectable contraceptive Known suspected secondary hypertension Mean sit SBP ≥ 180 mmHg mean sit DBP ≥ 110 mmHg visit placebo runin period Hepatic and/or renal dysfunction define follow laboratory parameter : Serum glutamatepyruvatetransaminase ( alanine aminotransferase ) serum glutamateoxaloacetatetransaminase ( aspartate aminotransferase ) &gt; 2 time upper limit normal range Serum creatinine &gt; 2.3 mg/dL ( &gt; 203 µmol/l ) Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; patient postrenal transplant one kidney Clinically relevant sodium depletion , hypokalaemia , hyperkalaemia Uncorrected volume depletion Primary aldosteronism Hereditary fructose intolerance Biliary obstructive disorder Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist History drug alcohol dependency within 6 month Chronic administration medication know affect blood pressure , except medication allow protocol Any investigational therapy within one month signing informed consent form Congestive heart failure ( NYHA functional class congestive heart failure ( CHF ) class IIIIV ) Unstable angina within past six month Stroke within past six month Myocardial infarction cardiac surgery within past six month Percutaneous transluminal coronary angioplasty ( PTCA ) within past six month Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve Patients insulindependent diabetes mellitus whose diabetes hast stable control least past three month define HbA1c ≥ 10 % Night shift worker routinely sleep daytime whose work hour include midnight 4:00 ante meridiem ( AM ) Known hypersensitivity component formulation Any clinical condition , opinion investigator would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>